摘要
目的:探讨重组人促红细胞生成素(rHuEPO)治疗不同水平内源性血清促红细胞生成素(sEPO)的骨髓增生异常综合征(MDS)患者贫血的临床疗效。方法:收集2019年1月至2023年9月新疆医科大学第二附属医院血液科诊治的MDS合并贫血患者56例,根据sEPO水平不同分为三组,分别为sEPO 0.05),治疗后三组RBC、Hb、HCT均较前升高,输血量较前显著降低,差异具有统计学意义(P < 0.05),且治疗后sEPO < 100 IU/L组RBC水平明显高于200~500 IU/L组的水平。结论:对于sEPO水平低于500 IU/L的MDS贫血患者实施rHuEPO治疗均能改善患者贫血状态,且sEPO水平偏低者临床疗效较好。
Objective: To investigate the clinical efficacy of recombinant human erythropoietin (rHuEPO) in the treatment of anemia in myelodysplastic syndrome (MDS) patients with different levels of endoge-nous serum erythropoietin (sEPO). Methods: A total of 56 patients with MDS complicated with ane-mia were collected from the Department of Hematology, the Second Affiliated Hospital of Xinjiang Medical University from January 2019 to September 2023. They were divided into three groups ac-cording to different sEPO levels, including 18 patients in sEPO 0.05). After treatment, RBC, Hb and HCT of the three groups were higher than before, and blood transfusion volume was significantly lower than before, with statistical significance (P < 0.05). After treatment, the levels of RBC in sEPO < 100 IU/L group were significantly higher than those in 200~500 IU/L group. Conclusion: For MDS pa-tients with anemia with sEPO level lower than 500 IU/L, rHuEPO therapy can improve the anemia status of patients, and for those with low sEPO level has good clinical efficacy.
出处
《临床医学进展》
2024年第2期2966-2971,共6页
Advances in Clinical Medicine
